TY - JOUR
T1 - Curcumin nanodisk-induced apoptosis in mantle cell lymphoma
AU - Singh, Amareshwar T.K.
AU - Ghosh, Mistuni
AU - Forte, Trudy M.
AU - Ryan, Robert O.
AU - Gordon, Leo I.
N1 - Funding Information:
This study is supported by grants from The North-western University Feinberg School of Medicine Department of Medicine Lymphoma Research Fund (L.I.G.), the Meyer Research Fund (L.I.G.), and the Philip Bligh Research Fund (L.I.G.). The work was also supported by National Institutes of Health (NIH) grant HL-64159 (R.O.R.) from the National Heart, Lung and Blood Institute and the NIH Small Business Initiative Research award 1R43CA141904 (T.M.F.) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. M.G. was supported by an American Heart Association Western States Affiliate Predoctoral Fellowship (#10PRE3600031).
PY - 2011/8
Y1 - 2011/8
N2 - Mantle cell lymphoma (MCL) is a pre-germinal center neoplasm characterized by cyclin D1 overexpression resulting from t(11;14)(q13;q32). Since MCL is incurable with standard lymphoma therapies, new treatment approaches are needed that target specific biologic pathways. In the present study, we investigated a novel drug delivery nanovehicle enriched with the bioactive polyphenol, curcumin (curcumin nanodisks; curcumin-ND). Cells treated with curcumin-ND showed a dose-dependent increase in apoptosis. This was accompanied by enhanced generation of reactive oxygen species (ROS). The antioxidant, N-acetylcysteine, inhibited curcumin-ND induced apoptosis, suggesting that ROS generation plays a role in curcumin action on MCL cells. Curcumin-ND decreased cyclin D1, pAkt, pIκB, and Bcl2 protein. In addition, enhanced FoxO3a and p27 expression as well as caspase-9, -3, and poly(ADP-ribose) polymerase (PARP) cleavage were observed. Curcumin-ND treatment led to enhanced G1 arrest in two cultured cell models of MCL.
AB - Mantle cell lymphoma (MCL) is a pre-germinal center neoplasm characterized by cyclin D1 overexpression resulting from t(11;14)(q13;q32). Since MCL is incurable with standard lymphoma therapies, new treatment approaches are needed that target specific biologic pathways. In the present study, we investigated a novel drug delivery nanovehicle enriched with the bioactive polyphenol, curcumin (curcumin nanodisks; curcumin-ND). Cells treated with curcumin-ND showed a dose-dependent increase in apoptosis. This was accompanied by enhanced generation of reactive oxygen species (ROS). The antioxidant, N-acetylcysteine, inhibited curcumin-ND induced apoptosis, suggesting that ROS generation plays a role in curcumin action on MCL cells. Curcumin-ND decreased cyclin D1, pAkt, pIκB, and Bcl2 protein. In addition, enhanced FoxO3a and p27 expression as well as caspase-9, -3, and poly(ADP-ribose) polymerase (PARP) cleavage were observed. Curcumin-ND treatment led to enhanced G1 arrest in two cultured cell models of MCL.
KW - Nanodisks
KW - apoptosis
KW - cell cycle
KW - curcumin
KW - mantle cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=79960406241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960406241&partnerID=8YFLogxK
U2 - 10.3109/10428194.2011.584253
DO - 10.3109/10428194.2011.584253
M3 - Article
C2 - 21699455
AN - SCOPUS:79960406241
SN - 1042-8194
VL - 52
SP - 1537
EP - 1543
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -
